Keyphrases
Heart Failure
100%
Medicare Beneficiaries
100%
Clinical Benefit
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Dapagliflozin
100%
Readmission
62%
Heart Failure with Preserved Ejection Fraction (HFpEF)
50%
Hospitalization
37%
Triple Therapy
37%
Treatment Eligible
37%
High Risk
25%
Adverse Outcomes
25%
Angiotensin-converting Enzyme Inhibitor (ACEi)
25%
Beta-blockers
25%
Clinical Trials
12%
Potential Gains
12%
Kidney Function
12%
Risk Reduction
12%
U.S. Food
12%
Type 1 Diabetes Mellitus (T1DM)
12%
Estimated Glomerular Filtration Rate
12%
Mortality Risk
12%
Claims Data
12%
Heart Failure Trials
12%
Disease-modifying Therapy
12%
Type I Diabetes
12%
Dialysis
12%
Heart Failure Management
12%
Diabetes Status
12%
Relative Risk Reduction
12%
1-year Outcome
12%
Patient Profile
12%
Absolute Risk Reduction
12%
Absolute Benefit
12%
Get With The Guidelines
12%
Medicine and Dentistry
Medicare
100%
Congestive Heart Failure
100%
Dapagliflozin
100%
Sodium-Glucose Cotransporter 2 Inhibitors
100%
Heart Failure with Reduced Ejection Fraction
50%
Adverse Outcome
25%
Risk Reduction
25%
Clinical Trial
12%
Diabetes
12%
Kidney Function
12%
Glomerular Filtration Rate
12%
Insulin Dependent Diabetes Mellitus
12%
Disease Modifying Therapy
12%
Relative Risk Reduction
12%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Dapagliflozin
100%
sodium glucose cotransporter-2 inhibitors
100%
Heart Failure with Reduced Ejection Fraction
50%
Adverse Outcome
25%
Clinical Trial
12%
Insulin Dependent Diabetes Mellitus
12%
Diseases
12%